Icosavax, Inc.
ICVX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.58 | -1.43 | -0.96 |
| FCF Yield | -4.90% | -4.48% | -9.70% | -3.66% |
| EV / EBITDA | -13.16 | -10.29 | -8.09 | -10.59 |
| Quality | ||||
| ROIC | -10.51% | -11.30% | -12.33% | -10.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.73 | 0.88 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 4.51% | 14.30% | -100.99% | 45.84% |
| Safety | ||||
| Net Debt / EBITDA | 2.18 | 5.06 | 1.65 | 1.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -146.15 | -209.37 | -225.49 | -162.47 |